NEWS
-
2026/07/15 Correctseq
Chen Jia's Group Develops An Efficient VLP Delivery System For In Vivo Cytosine Base Editing
Recently, the research group led by Dr. Chen Jia, Scientific Founder of CorrectSequence Therapeutics and a professor at the School of Life Science and Technology (SLST), ShanghaiTech University, together with collaborators, made important advances in the in vivo delivery of cytosine base editors using virus-like particles. The findings were published in Nature Biotechnology under the title “Efficient in vivo cytosine base editing via virus-like particles with uracil DNA glycosylase inhibition.” By engineering both the base editor and virus-like particle (VLP) packaging strategies, the research team developed an efficient in vivo cytosine base editing system, tBE-VLP4. By delivering the transformer base editor (tBE) via VLPs, the system enabled efficient C-to-T editing in mice.
-
2026/06/02 Correctseq
Shanghai, June 2, 2026 — CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for severe diseases, announced that the first sickle cell disease (SCD) patient being treated in China with its high-precision base-editing therapy CS-206 has remained free of vaso-occlusive crises (VOCs) for more than 15 months following engraftment. Starting from 60 Days after the last red-cell transfusion, the patient has remained free from VOCs and anemia for 13 consecutive months, achieving the primary efficacy endpoint. The follow-up data demonstrated favorable safety and efficacy of CS-206.
-
2026/05/11 Correctseq
May 11, 2026, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announ
-
2026/04/24 China Daily
China Daily | Chinese Researchers Debut Breakthrough DNA Repair Tool for Genetic Disorders
A domestically developed gene-editing therapy has successfully treated patients with beta-thalassemia, allowing them to live without the need for lifelong blood transfusions, according to a study published on Wednesday in the journal Nature.
-
2026/04/09 Xinhua Net
In a milestone for genetic medicine, researchers in China have reported the world's first clinical success using a revolutionary "base-editing" technique to treat patients with a severe inherited blood disorder.
-
2026/04/09 Correctseq
In a breakthrough for gene therapy, the international academic journal Nature has published a landmark clinical study detailing the successful use of a novel base-editing drug to treat β-thalassemia.J
-
2025/12/01 Correctseq
CorrectSequence Therapeutics to Participate in the 67th ASH Annual Meeting
December 1, 2025, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aiming to use the innovative gene editing technology to help people with severe diseases,
-
2025/11/07 Correctseq
The World's First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia
Shanghai, China, November 6, 2025 — CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, today announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing therapy CS-121 targeting APOC3 for chylomicronemia / hypertriglyceridemia has successfully completed dosing and been discharged from the hospital.